OBJECTIVE: Among causes for congenital heart disease (CHD) chromosomal abnormalities account for approximately 20%. We aimed to evaluate the utility of chromosomal microarray as the first tier test for chromosomal abnormalities in fetuses with CHD and to identify different types of chromosomal abnormalities association to CHD subgroups. STUDY DESIGN: This is a retrospective data from 336 pregnancies diagnosed with CHD between 2011 and 2016 were reviewed. Total of 209 prenatal cases of CHD were investigated using single nucleotide polymorphism (SNP) during the study period. After complete analysis, cohort was divided into two groups, isolated CHD and nonisolated CHD (fetuses with extracardiac anomalies). Classification of chromosomal abnormalities were done based on American college of genetics guidelines into numerical chromosomal abnormalities (NCA) which included aneuploidies and partial aneuploidies, and copy number variants (CNV) which for the purposes of this study was further classified into pathogenic CNV (DiGeorge, other), and variable of unknown significance (VUS) or likely benign. RESULTS: Pathogenic chromosomal abnormalities were identified in 43.8% (n¼92), with 69.5% (n¼64) of them being numerical abnormalities, and 15.2% (n¼14) being pathogenic CNV. The detection rate for VUS or likely benign was 15.2% (n¼14). Pathogenic chromosomal abnormalities (NCA and pathogenic CNV) were 22.1% (n¼32) in the isolated CHD group, and 70.8% (n¼46) in the non-isolated CHD group (P< 0.0001).
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Subgroup analysis of different types of CHD was also conducted by dividing the cohort into 8 groups (see table) . Overall atrioventricular septal defects (AVSD) were the most common to be associated with chromosomal abnormalities (31.5%) followed by conotruncal defects 29.3%. Pathogenic CNV were most common in conotruncal defects group (10.8%) CONCLUSION: Our study demonstrates SNP array is a reliable and high resolution method and should be used as first tier test for all fetuses with CHD in clinical practice, regardless of the types of CHD or whether combined with extracardiac defects or not.
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